Axitinib in advanced renal cell carcinoma: real-life data and dose modification audit
نویسندگان
چکیده
منابع مشابه
Targeted treatments in advanced renal cell carcinoma: focus on axitinib
Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer cell. Axitinib is a third-generation inhibitor of vascular endothelial growth factor receptor and...
متن کاملAxitinib in Metastatic Renal Cell Carcinoma
Targeted agents have revolutionized the management of metastatic renal cell carcinoma (RCC). Axitinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), has been an important addition to currently available therapies for advanced RCC. Its ability to inhibit VEGFRs at nanomolar concentrations distinguishes it as a potent tyrosine kinase inhibitor, with increased selectivity fo...
متن کاملAdverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice.
OBJECTIVE The aim of the study was to assess the safety and efficacy of everolimus therapy for advanced renal cell carcinoma in Japanese patients receiving real-world care. METHODS Patients who had been treated with everolimus for advanced renal cell carcinoma at 39 Japanese medical centers between January 2010 and November 2011 were retrospectively investigated to assess adverse events and t...
متن کاملAxitinib: Newly Approved for Renal Cell Carcinoma
4503 (Rini et al.) from the 2012 ASCO annual meeting, as well as information on specialty pharmacies and patient assistance. SEE PAGE XXX SEE PAGE 298 erythrodysesthesia (hand-foot syndrome), but this was in a heavily pretreated population. The question of whether these side effects will remain as pronounced in a first-line setting is still unanswered. Of equal importance is whether or not the ...
متن کاملPhase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
Background Axitinib, an inhibitor of vascular endothelial growth factor receptors (VEGFRs), is approved for second-line treatment of advanced renal cell carcinoma (aRCC). Pembrolizumab is a humanized monoclonal antibody that blocks binding of the immune-checkpoint receptor programmed death-1 (PD 1) to its ligands (PD-L1/2). Combination treatment with PD-1 and VEGFR inhibitors has shown benefit ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Medicine
سال: 2019
ISSN: 1470-2118,1473-4893
DOI: 10.7861/clinmedicine.19-2-s54